Tags

Type your tag names separated by a space and hit enter

Pathogenicity and treatment of Bartonella infections.
Int J Antimicrob Agents. 2014 Jul; 44(1):16-25.IJ

Abstract

Bartonella spp. are responsible for emerging and re-emerging diseases around the world. The majority of human infections are caused by Bartonella henselae, Bartonella quintana and Bartonella bacilliformis, although other Bartonella spp. have also been associated with clinical manifestations in humans. The severity of Bartonella infection correlates with the patient's immune status. Clinical manifestations can range from benign and self-limited to severe and life-threatening disease. Clinical conditions associated with Bartonella spp. include local lymphadenopathy, bacteraemia, endocarditis, and tissue colonisation resulting in bacillary angiomatosis and peliosis hepatis. Without treatment, Bartonella infection can cause high mortality. To date, no single treatment is effective for all Bartonella-associated diseases. In the absence of systematic reviews, treatment decisions for Bartonella infections are based on case reports that test a limited number of patients. Antibiotics do not significantly affect the cure rate in patients with Bartonella lymphadenopathy. Patients with Bartonella spp. bacteraemia should be treated with gentamicin and doxycycline, but chloramphenicol has been proposed for the treatment of B. bacilliformis bacteraemia. Gentamicin in combination with doxycycline is considered the best treatment regimen for endocarditis, and erythromycin is the first-line antibiotic therapy for the treatment of angioproliferative lesions. Rifampicin or streptomycin can be used to treat verruga peruana. In this review, we present recent data and recommendations related to the treatment of Bartonella infections based on the pathogenicity of Bartonella spp.

Authors+Show Affiliations

URMITE UMR 6236, CNRS-IRD, Faculté de Médecine Aix Marseille Universite, 27 Bd. Jean Moulin, 13385 Marseille cedex 05, France.URMITE UMR 6236, CNRS-IRD, Faculté de Médecine Aix Marseille Universite, 27 Bd. Jean Moulin, 13385 Marseille cedex 05, France. Electronic address: Didier.raoult@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24933445

Citation

Angelakis, Emmanouil, and Didier Raoult. "Pathogenicity and Treatment of Bartonella Infections." International Journal of Antimicrobial Agents, vol. 44, no. 1, 2014, pp. 16-25.
Angelakis E, Raoult D. Pathogenicity and treatment of Bartonella infections. Int J Antimicrob Agents. 2014;44(1):16-25.
Angelakis, E., & Raoult, D. (2014). Pathogenicity and treatment of Bartonella infections. International Journal of Antimicrobial Agents, 44(1), 16-25. https://doi.org/10.1016/j.ijantimicag.2014.04.006
Angelakis E, Raoult D. Pathogenicity and Treatment of Bartonella Infections. Int J Antimicrob Agents. 2014;44(1):16-25. PubMed PMID: 24933445.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pathogenicity and treatment of Bartonella infections. AU - Angelakis,Emmanouil, AU - Raoult,Didier, Y1 - 2014/05/09/ PY - 2014/03/20/received PY - 2014/04/30/accepted PY - 2014/6/17/entrez PY - 2014/6/17/pubmed PY - 2015/1/27/medline KW - Bartonella spp. KW - Pathogenicity KW - Treatment SP - 16 EP - 25 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 44 IS - 1 N2 - Bartonella spp. are responsible for emerging and re-emerging diseases around the world. The majority of human infections are caused by Bartonella henselae, Bartonella quintana and Bartonella bacilliformis, although other Bartonella spp. have also been associated with clinical manifestations in humans. The severity of Bartonella infection correlates with the patient's immune status. Clinical manifestations can range from benign and self-limited to severe and life-threatening disease. Clinical conditions associated with Bartonella spp. include local lymphadenopathy, bacteraemia, endocarditis, and tissue colonisation resulting in bacillary angiomatosis and peliosis hepatis. Without treatment, Bartonella infection can cause high mortality. To date, no single treatment is effective for all Bartonella-associated diseases. In the absence of systematic reviews, treatment decisions for Bartonella infections are based on case reports that test a limited number of patients. Antibiotics do not significantly affect the cure rate in patients with Bartonella lymphadenopathy. Patients with Bartonella spp. bacteraemia should be treated with gentamicin and doxycycline, but chloramphenicol has been proposed for the treatment of B. bacilliformis bacteraemia. Gentamicin in combination with doxycycline is considered the best treatment regimen for endocarditis, and erythromycin is the first-line antibiotic therapy for the treatment of angioproliferative lesions. Rifampicin or streptomycin can be used to treat verruga peruana. In this review, we present recent data and recommendations related to the treatment of Bartonella infections based on the pathogenicity of Bartonella spp. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/24933445/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(14)00118-6 DB - PRIME DP - Unbound Medicine ER -